Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment Biotech
Tryp Therapeutics Announces Results of First Patient Dosed in Its Phase II Clinical Trial for
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions
Awakn Life Sciences Completes World’s First Ketamine Study For A Range Of Behavioral Addictions Collectively,
Tryp Therapeutics Doses First Patient in Phase II Psilocybin-assisted Therapy Clinical Trial Phase II trial
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with
NeonMind Announces Positive Preclinical Results Demonstrating the Efficacy of Psilocybin in Reducing Weight Gain in
Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida
Recruitment for an upcoming trial – Psilocybin as a Treatment for Anorexia Nervosa: A Pilot
Sydney Researchers Awarded Over $2.2 Million By Australian Government To Study MDMA, Psilocybin University of
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral
Tryp Therapeutics: An Interview with Jim Gilligan Ph.D. Over-eating disorders occur when the brain is
Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder SAN DIEGO
Study suggests psychedelics promote positive mental health through increased spirituality and emotion regulation A recent
Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI
TRYP THERAPEUTICS SUBMITS IND APPLICATION FOR PHASE 2A CLINICAL TRIAL IN EATING DISORDERS Can shrooms
Tryp Therapeutics Submits Ind Application For Phase 2a Clinical Trial In Eating Disorders SAN DIEGO
Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials
TRYP THERAPEUTICS COMPLETES PSYCHOTHERAPY TRAINING FOR PHASE 2A STUDY AT THE UNIVERSITY OF FLORIDA The
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral
Dr. Jennifer Miller | Principal Investigator, Tryp Therapeutics Tryp Therapeutics Inc. (TRYP), is conducting a
Magic mushrooms’ for eating disorders? Drug company running trials at B.C. university Dr. C. Laird
